title: Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
authors.affiliation: Center for the Study of Myelofibrosis, IRCCS Policlinico S, Matteo Foundation, Pavia, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Barosi
authors.affiliation: Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: M-J
authors.initials: MJ
authors.lastname: Zhang
authors.affiliation: Haematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, UK.
authors.forename: R Peter
authors.initials: RP
authors.lastname: Gale
mesh_terms: D005500:Follow-Up Studies; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors*; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000401:mortality*; D009570:Nitriles; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects*; D011743:Pyrimidines; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate
chemical_list: D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; D053612:Janus Kinases